PMID- 28656091
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220410
IS  - 2008-3866 (Print)
IS  - 2008-3874 (Electronic)
IS  - 2008-3866 (Linking)
VI  - 20
IP  - 5
DP  - 2017 May
TI  - A review of the effects of Berberis vulgaris and its major component, berberine, 
      in metabolic syndrome.
PG  - 557-568
LID - 10.22038/IJBMS.2017.8682 [doi]
AB  - Metabolic syndrome (MetS), characterized by a cluster of metabolic abnormalities 
      including hypertension, obesity, type 2 diabetes mellitus (T2DM) and 
      dyslipidemia, is a well-known cardiovascular risk factor (CVRF). Cardiovascular 
      disease (CVD) represents a massive healthcare burden worldwide. In recent years, 
      with regard to the adverse effects of synthetic drugs, increasing attention has 
      been paid by researchers to herbal medicines for a variety of disorders such as 
      CVD. A large body of literature supports different pharmacological actions of 
      Berberis vulgaris (B. vulgaris) and its active component, berberine (BBR), such 
      as antidiabetic, antiobesity, hypotensive and hypolipidemic properties that could 
      be interesting in the management of MetS associated with high CVD risk. Numerous 
      preclinical in vitro and in vivo studies support all these effects. In this 
      review, we evaluated the most related original articles to discover the role of 
      B. vulgaris on various constituents of MetS and CVRF comprising dyslipidemia, 
      obesity, high blood pressure and high blood glucose. This review suggests a 
      potential role of B. vulgaris and BBR in the managing of MetS; nevertheless more 
      investigations, especially reliable clinical trials, need to be accomplished to 
      evaluate their effectiveness.
FAU - Tabeshpour, Jamshid
AU  - Tabeshpour J
AD  - Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad 
      University of Medical Sciences, Mashhad, Iran.
AD  - Student Research Committee, Mashhad University of Medical Sciences, Mashhad, 
      Iran.
FAU - Imenshahidi, Mohsen
AU  - Imenshahidi M
AD  - Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad 
      University of Medical Sciences, Mashhad, Iran.
FAU - Hosseinzadeh, Hossein
AU  - Hosseinzadeh H
AD  - Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad 
      University of Medical Sciences, Mashhad, Iran.
AD  - Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, 
      Iran.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Iran
TA  - Iran J Basic Med Sci
JT  - Iranian journal of basic medical sciences
JID - 101517966
PMC - PMC5478784
OTO - NOTNLM
OT  - Berberine
OT  - Berberis vulgaris
OT  - Cardiovascular disease
OT  - Diabetes
OT  - Dyslipidemia
OT  - Hypertension
OT  - Metabolic syndrome
EDAT- 2017/06/29 06:00
MHDA- 2017/06/29 06:01
PMCR- 2017/05/01
CRDT- 2017/06/29 06:00
PHST- 2017/06/29 06:00 [entrez]
PHST- 2017/06/29 06:00 [pubmed]
PHST- 2017/06/29 06:01 [medline]
PHST- 2017/05/01 00:00 [pmc-release]
AID - IJBMS-20-557 [pii]
AID - 10.22038/IJBMS.2017.8682 [doi]
PST - ppublish
SO  - Iran J Basic Med Sci. 2017 May;20(5):557-568. doi: 10.22038/IJBMS.2017.8682.